SCHEMBL4363907

SCHEMBL4363907

C/C(=C\c1ccc(-c2cccc(CNCC(=O)c3ccccc3)c2)cc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.43
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
PGGT1B P53609 1/20 0.42
AOC3 Q16853 2/20 0.41
PTGS2 P35354 1/20 0.41
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
MEP1B Q16820 1/20 0.40
VSIR Q9H7M9 1/20 0.40
BCL2 P10415 1/20 0.40
SENP1 Q9P0U3 3/20 0.39
TBXAS1 P24557 1/20 0.39
TP53 P04637 1/20 0.39
BCHE P06276 1/20 0.39
ERN1 O75460 1/20 0.39
CFD P00746 1/20 0.38
SENP2 Q9HC62 1/20 0.38
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4363911 1.00 AKR1C3 (0.43) AKR1C3FNTAFNTBPGGT1BAOC3
SCHEMBL6183336 0.84 SENP1 (0.55) AOC3SENP1ERN1CFDSENP2
SCHEMBL6183341 0.84 SENP1 (0.55) AOC3SENP1ERN1CFDSENP2
SCHEMBL4219792 0.80 KDM4E (0.41) AKR1C3FNTAFNTBPGGT1B
SCHEMBL4209272 0.80 KDM4E (0.41) AKR1C3FNTAFNTBPGGT1B
SCHEMBL6184063 0.76 MME (0.49) FNTAFNTBPGGT1BPTGS2BCL2
SCHEMBL2847859 0.76 TPH1 (0.60) FNTAFNTBPGGT1B
SCHEMBL2851699 0.76 TPH1 (0.60) FNTAFNTBPGGT1B
SCHEMBL2847857 0.76 TPH1 (0.60) FNTAFNTBPGGT1B
SCHEMBL6158614 0.76 ITGB1 (0.47) FNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA AKR1C3 901/4885FNTA 2068/4885FNTB 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.